BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. Journal of Child and Adolescent Psychopharmacology 2019;29:168-80. [DOI: 10.1089/cap.2018.0115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opinion on Drug Safety 2020;19:1419-44. [DOI: 10.1080/14740338.2020.1820985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Coustals N, Ménard ML, Cohen D. Aripiprazole in Children and Adolescents. J Child Adolesc Psychopharmacol 2021;31:4-32. [PMID: 32931315 DOI: 10.1089/cap.2020.0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Wang F, Wen F, Yu L, Yan J, Liu J, Li Y, Cui Y. The efficacy and safety in attention deficit hyperactivity disorder of second-generation antipsychotics and other medications for hyperactivity in children and adolescents with autism: a meta-analysis. Int Clin Psychopharmacol 2021;36:109-16. [PMID: 33492013 DOI: 10.1097/YIC.0000000000000349] [Reference Citation Analysis]
4 D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA guideline working group. Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review. BMC Psychiatry 2020;20:561. [PMID: 33238921 DOI: 10.1186/s12888-020-02956-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 2021;20:244-75. [PMID: 34002501 DOI: 10.1002/wps.20881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020;19:214-32. [PMID: 32394557 DOI: 10.1002/wps.20765] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
7 Forster J, Duis J, Butler MG. Pharmacogenetic Testing of Cytochrome P450 Drug Metabolizing Enzymes in a Case Series of Patients with Prader-Willi Syndrome. Genes (Basel) 2021;12:152. [PMID: 33498922 DOI: 10.3390/genes12020152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA Guideline Working Group. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health Qual Life Outcomes 2021;19:33. [PMID: 33494757 DOI: 10.1186/s12955-021-01669-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ahlberg R, Garcia-Argibay M, Hirvikoski T, Boman M, Chen Q, Taylor MJ, Frans E, Bölte S, Larsson H. Shared familial risk factors between autism spectrum disorder and obesity - a register-based familial coaggregation cohort study. J Child Psychol Psychiatry 2021. [PMID: 34881437 DOI: 10.1111/jcpp.13538] [Reference Citation Analysis]
10 Holmes GL. Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children. Paediatr Drugs 2021;23:55-73. [PMID: 33230678 DOI: 10.1007/s40272-020-00428-w] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pistollato F, Forbes-Hernández TY, Calderón Iglesias R, Ruiz R, Elexpuru Zabaleta M, Cianciosi D, Giampieri F, Battino M. Pharmacological, non-pharmacological and stem cell therapies for the management of autism spectrum disorders: A focus on human studies. Pharmacol Res 2020;152:104579. [PMID: 31790820 DOI: 10.1016/j.phrs.2019.104579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
12 Bell E, Boyce P, Porter RJ, Bryant RA, Malhi GS. Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention. CNS Drugs 2021;35:619-41. [PMID: 34019255 DOI: 10.1007/s40263-021-00823-y] [Reference Citation Analysis]
13 Al-huseini S, Al-barhoumi A, Al-balushi M, Al-hosni A, Al-mahrouqi T, Al-mahrizi B, Jaju S, Mirza H, Salloum-asfar S. Effectiveness and Adverse Effects of Risperidone in Children with Autism Spectrum Disorder in a Naturalistic Clinical Setting at a University Hospital in Oman. Autism Research and Treatment 2022;2022:1-7. [DOI: 10.1155/2022/2313851] [Reference Citation Analysis]
14 Seifert R. Drugs for Treatment of Schizophrenia. Basic Knowledge of Pharmacology. Cham: Springer International Publishing; 2019. pp. 345-55. [DOI: 10.1007/978-3-030-18899-3_29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Cookson J, Pimm J. Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych advances. [DOI: 10.1192/bja.2021.49] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lai MC, Anagnostou E, Wiznitzer M, Allison C, Baron-Cohen S. Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person-environment fit. Lancet Neurol 2020;19:434-51. [PMID: 32142628 DOI: 10.1016/S1474-4422(20)30034-X] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
17 Amini A, Namvarpour Z, Namvarpour M, Raoofi A. Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure. Life Sci 2020;258:118197. [PMID: 32781059 DOI: 10.1016/j.lfs.2020.118197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dhaliwal KK, Orsso CE, Richard C, Haqq AM, Zwaigenbaum L. Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder. Int J Mol Sci 2019;20:E3285. [PMID: 31277383 DOI: 10.3390/ijms20133285] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
19 Meza N, Rees R, Escobar Liquitay CM, Franco JV, Sguassero Y, Williams K, Pringsheim T, Rojas V, Madrid E; Cochrane Developmental, Psychosocial and Learning Problems Group. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014965] [Reference Citation Analysis]
20 Siafis S, Çıray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, San José Cáceres A, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism 2022;13:10. [PMID: 35246237 DOI: 10.1186/s13229-022-00488-4] [Reference Citation Analysis]
21 Yuge K, Nagamitsu S, Ishikawa Y, Hamada I, Takahashi H, Sugioka H, Yotsuya O, Mishima K, Hayashi M, Yamashita Y. Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. BMC Psychiatry 2020;20:445. [PMID: 32912180 DOI: 10.1186/s12888-020-02847-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Bartram LA, Lozano J, Coury DL. Aripiprazole for treating irritability associated with autism spectrum disorders. Expert Opinion on Pharmacotherapy 2019;20:1421-7. [DOI: 10.1080/14656566.2019.1626825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
23 Joon P, Kumar A, Parle M. What is autism? Pharmacol Rep 2021;73:1255-64. [PMID: 33694100 DOI: 10.1007/s43440-021-00244-0] [Reference Citation Analysis]
24 Seifert R, Schirmer B. A simple mechanistic terminology of psychoactive drugs: a proposal. Naunyn Schmiedebergs Arch Pharmacol 2020;393:1331-9. [PMID: 32535698 DOI: 10.1007/s00210-020-01918-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Fletcher S, Pawliuk C, Ip A, Oberlander T, Siden H. Symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review protocol. JBI Evid Synth 2021;19:1251-8. [PMID: 33165173 DOI: 10.11124/JBIES-20-00001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Vuori M, Sourander A, Aronen ET, Kronström K, Saastamoinen LK. Relative Age and the Use of Second-Generation Antipsychotics from 7 to 17 Years of Age: A Population-Based Register Study. J Child Adolesc Psychopharmacol 2021. [PMID: 34619034 DOI: 10.1089/cap.2021.0053] [Reference Citation Analysis]
27 Houghton R, van den Bergh J, Law K, Liu Y, de Vries F. Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders. Autism Res 2021;14:1800-14. [PMID: 34080319 DOI: 10.1002/aur.2541] [Reference Citation Analysis]